Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Phase II Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral AND017 to Treat Anemia in Nondialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients

NCT05035641 is registered in ClinicalTrials.gov with Kind Pharmaceuticals LLC as lead sponsor.

NCT NCT05035641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05035641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Phase II Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral AND017 to Treat Anemia in Nondialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients
Lead sponsor
Kind Pharmaceuticals LLC
Phase
Phase 2
Overall status
Completed
Start date
October 18, 2021
Completion date
July 24, 2023
Enrollment
113 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

renal anemia